Latest Articles
Biontech prepares FDA application after strong phase II results in endometrial cancer - medwatch.com
Biontech prepares FDA application after strong phase II results in endometrial cancer medwatch.com
Published: April 13, 2026, 12:14 p.m.
Endometrial cancer trial: BioNTech (Nasdaq: BNTX) ADC hits Phase 2 goal - Stock Titan
Endometrial cancer trial: BioNTech (Nasdaq: BNTX) ADC hits Phase 2 goal Stock Titan
Published: April 13, 2026, 11:55 a.m.
A Look At BioNTech (BNTX) Valuation After Positive Phase 2 HER2 Endometrial Cancer Data - Sahm
A Look At BioNTech (BNTX) Valuation After Positive Phase 2 HER2 Endometrial Cancer Data Sahm
Published: April 13, 2026, 10:35 a.m.
GSK (NYSE: GSK) reports Mo-Rez data in ovarian, endometrial cancer - Stock Titan
GSK (NYSE: GSK) reports Mo-Rez data in ovarian, endometrial cancer Stock Titan
Published: April 13, 2026, 10:23 a.m.
Data From the CARE Trial in Recurrent/Advanced Endometrial Cancer - OncLive
Data From the CARE Trial in Recurrent/Advanced Endometrial Cancer OncLive
Published: April 12, 2026, 9:28 p.m.
Efficacy of Pamirtecan in HER2-Expressing Endometrial Cancer - OncLive
Efficacy of Pamirtecan in HER2-Expressing Endometrial Cancer OncLive
Published: April 12, 2026, 9:01 p.m.
Dr Pothuri on Preliminary Data With Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer - OncLive
Dr Pothuri on Preliminary Data With Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer OncLive
Published: April 12, 2026, 9 p.m.
Encouraging Activity in Poor-Risk Endometrial Cancer With HER2-Targeted Novel Drug - MedPage Today
Encouraging Activity in Poor-Risk Endometrial Cancer With HER2-Targeted Novel Drug MedPage Today
Published: April 12, 2026, 8:01 p.m.
A Look At BioNTech (BNTX) Valuation After Positive Phase 2 HER2 Endometrial Cancer Data - simplywall.st
A Look At BioNTech (BNTX) Valuation After Positive Phase 2 HER2 Endometrial Cancer Data simplywall.st
Published: April 12, 2026, 7:29 p.m.
Mocertatug Rezetecan Displays Early Efficacy, Tolerability in PROC and Endometrial Cancer - OncLive
Mocertatug Rezetecan Displays Early Efficacy, Tolerability in PROC and Endometrial Cancer OncLive
Published: April 12, 2026, 6:25 p.m.
Link copied to clipboard!